EXEL vs NBIX
Exelixis, Inc. and Neurocrine Biosciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | EXEL | NBIX |
|---|---|---|
| Revenue | $2.3B | $2.9B |
| Net income | $782.6M | $478.6M |
| Gross margin | 96.4% | 98.2% |
| Net margin | 33.7% | 16.7% |
| Return on equity | 35.5% | 16.4% |
| Diluted EPS | $2.78 | $4.67 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $875.8M | $748.7M |
| Equity | $2.2B | $3.3B |
| Net debt / equity | −0.66× | — |
| Current ratio | 3.56× | 3.39× |
| Revenue CAGR 5y | 18.6% | 22.3% |
| Profit CAGR 5y | 47.6% | 3.3% |
NBIX bills 1.2× the revenue of EXEL, and EXEL keeps more of each dollar of revenue as profit (33.7% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | EXEL | NBIX |
|---|---|---|
| FY2025 | $2.3B | $2.9B |
| FY2024 | $2.2B | $2.4B |
| FY2023 | $1.8B | $1.9B |
| FY2022 | $1.6B | $1.5B |
| FY2021 | $1.4B | $1.1B |
| FY2020 | $987.5M | $1.0B |
| FY2019 | $967.8M | $788.1M |
| FY2018 | $853.8M | $451.2M |
| FY2017 | $452.5M | $161.6M |
| FY2016 | $191.5M | $15.0M |
Net income by year
Bottom line
| Fiscal year | EXEL | NBIX |
|---|---|---|
| FY2025 | $782.6M | $478.6M |
| FY2024 | $521.3M | $341.3M |
| FY2023 | $207.8M | $249.7M |
| FY2022 | $182.3M | $154.5M |
| FY2021 | $231.1M | $89.6M |
| FY2020 | $111.8M | $407.3M |
| FY2019 | $321.0M | $37.0M |
| FY2018 | $690.1M | $21.1M |
| FY2017 | $154.2M | $-142.5M |
| FY2016 | $-70.2M | $-141.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry